The second pathogenic mutation has been identified in the tumor suppressor gene MUTYH. Recent studies point to a low risk of cancer in carriers of monoallelic pathogenic variants in MUTYH in HBOC (22, 36). This evidence concerns the gene MUTYH and cancer.